LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Aandelen Lijst・Kura Oncology Inc

Kura Oncology Inc

Gesloten

SectorGezondheidszorg

8.74 -0.34

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.55

Max

8.74

Belangrijke statistieken
By Trading Economics
Inkomsten	7.7M -73M
Verkoop	929K 18M
EPS	-0.828
Winstmarge	-401.495
Werknemers	260
EBITDA	7.4M -78M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+221.62% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-42M 802M
Vorige openingsprijs	9.08
Vorige sluitingsprijs	8.74

Nieuwssentiment

By Acuity

24%

76%

56 / 344 Rangschikking in Healthcare

Kura Oncology Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 jun 2026, 19:20 UTC

Belangrijke Marktbewegers

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

5 jun 2026, 21:27 UTC

Winsten

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 jun 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

5 jun 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

5 jun 2026, 20:20 UTC

Acquisities, Fusies, Overnames

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 jun 2026, 20:19 UTC

Acquisities, Fusies, Overnames

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 jun 2026, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

5 jun 2026, 19:26 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

5 jun 2026, 19:26 UTC

Marktinformatie

Hog Futures Tumble to Close Week -- Market Talk

5 jun 2026, 19:10 UTC

Marktinformatie

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 jun 2026, 19:03 UTC

Marktinformatie

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 jun 2026, 18:59 UTC

Marktinformatie

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 jun 2026, 18:47 UTC

Marktinformatie

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 jun 2026, 18:34 UTC

Marktinformatie

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 jun 2026, 18:33 UTC

Acquisities, Fusies, Overnames

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 jun 2026, 17:50 UTC

Winsten

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 jun 2026, 17:27 UTC

Marktinformatie

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 jun 2026, 16:48 UTC

Acquisities, Fusies, Overnames

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 jun 2026, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

5 jun 2026, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

5 jun 2026, 16:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

5 jun 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

5 jun 2026, 15:44 UTC

Acquisities, Fusies, Overnames

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 jun 2026, 15:26 UTC

Marktinformatie

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5 jun 2026, 15:25 UTC

Winsten

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5 jun 2026, 15:16 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

5 jun 2026, 15:16 UTC

Marktinformatie

Zcash Tumbles After Exploit Found -- Market Talk

5 jun 2026, 15:09 UTC

Marktinformatie

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

5 jun 2026, 15:07 UTC

Marktinformatie

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

5 jun 2026, 15:05 UTC

Marktinformatie

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Peer Vergelijking

Prijswijziging

Kura Oncology Inc Prognose

Koersdoel

By TipRanks

221.62% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 28.11 USD 221.62%

Hoogste 40 USD

Laagste 15 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Kura Oncology Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Kura Oncology Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

56 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.